Abstract Body

Pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine has been demonstrated to effectively prevent new HIV infections among men who have sex with men (MSM). It has recently been shown that on demand PrEP use, in which individuals take PrEP just before and after sexual contact, can be just as effective as daily PrEP in preventing HIV infections. The high cost of PrEP is still a primary limitation in its use for HIV prevention. The aim of this study was to compare the epidemiological impact and cost-effectiveness of both daily and on demand PrEP compared to no PrEP.

A deterministic mathematical model was calibrated to the well-defined Dutch HIV epidemic among MSM. We aimed to predict the impact of PrEP targeted to 10% of the most sexually active individuals (median 4,500 MSM/year) over the coming 12 years, including two years of scale-up. Cost-effectiveness ratios were calculated to predict the cost-effectiveness of daily (€7,099/year) and on demand (€3,550/year) PrEP, and prevented infections were calculated to predict the epidemic impact. A decrease of 50% in the price of PrEP was considered in a sensitivity analysis, given that generic PrEP may soon become available. Cost-effectiveness ratios below €20,000 were considered to be cost-effective in this analysis.

Targeting PrEP to 10% of the most sexually active individuals was predicted to prevent 14.0% (interquartile range [IQR] 11.9%-16.3%) of new infections over the coming 12 years compared to no PrEP usage. Daily PrEP was predicted to cost €36,300 per quality adjusted life year (QALY) gained (IQR €34,000-€45,100). On demand dosing of PrEP has the potential to cut the cost per QALY gained by more than half to a cost-effective €17,700 (IQR €16,500-€22,200) per QALY gained over 12 years compared to no PrEP usage. This cost per QALY can be further reduced to €8,400 (IQR €7,700-€10,700) if the cost of on demand PrEP is reduced by 50%. If increasing numbers of patients are diagnosed and placed on treatment early, however, PrEP will have a diminished impact on the epidemic. This can result in the cost per QALY gained of on demand PrEP to increase to as much as €32,400 with full-price PrEP, and €16,200 with reduced-price PrEP.

The use of PrEP is only cost-effective when used on demand, and can become far more cost-effective when generic PrEP becomes available. The precise cost-effectiveness estimate is, however, dependent upon the impact of earlier treatment initiation on the future HIV epidemic.